{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T01:29:01Z","timestamp":1695778141424},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[1986,12,1]],"date-time":"1986-12-01T00:00:00Z","timestamp":533779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[1986,12,1]],"date-time":"1986-12-01T00:00:00Z","timestamp":533779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[1986,12]]},"DOI":"10.1007\/bf00173511","type":"journal-article","created":{"date-parts":[[2004,8,15]],"date-time":"2004-08-15T21:01:40Z","timestamp":1092603700000},"page":"377-381","source":"Crossref","is-referenced-by-count":10,"title":["Recombinant gamma interferon in advanced breast cancer: A phase II trial"],"prefix":"10.1007","volume":"4","author":[{"given":"Hyman B.","family":"Muss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Caponera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia J.","family":"Zekan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Don V.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J.","family":"Stuart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick","family":"Richards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Robert","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth A.","family":"Levin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven D.","family":"Reich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert L.","family":"Capizzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF00173511_CR1","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/0014-2964(80)90237-6","volume":"16","author":"F Balkwill","year":"1980","unstructured":"Balkwill F, Taylor-Papadimitriou J, Fantes KH, Sebesteny A: Human lymphoblastoid interferon can inhibit the growth of human breast cancer xenografts in athymic (nude) mice. Eur J Cancer 16:569\u2013573, 1980","journal-title":"Eur J Cancer"},{"key":"BF00173511_CR2","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1200\/JCO.1984.2.4.336","volume":"2","author":"JM Kirkwood","year":"1984","unstructured":"Kirkwood JM, Ernstoff MS: Interferons in the treatment of human cancer. J Clin Oncol 2:336\u2013352, 1984","journal-title":"J Clin Oncol"},{"key":"BF00173511_CR3","doi-asserted-by":"crossref","first-page":"399","DOI":"10.7326\/0003-4819-93-3-399","volume":"93","author":"J Gutterman","year":"1980","unstructured":"Gutterman J, Blumenschein R, Alexanian R, Yap H-Y, Buzdar AU, Cabanillas F, Hortobagyi GN, Hersh EM, Rasmussen SL, Harmon M, Kramer M, Pestka S: Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma and malignant lymphoma. Ann Intern Med 93:399\u2013406, 1980","journal-title":"Ann Intern Med"},{"key":"BF00173511_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-97-1-1","volume":"97","author":"E Borden","year":"1982","unstructured":"Borden E, Holland JF, Dao T, Gutterman JU, Wiener L, Chang Y-C, Patel J: Leukocyte-derived interferon (alpha) in human breast carcinoma: The American Cancer Society phase II trial. Ann Intern Med 97:1\u20136, 1982","journal-title":"Ann Intern Med"},{"key":"BF00173511_CR5","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1089\/jir.1982.2.593","volume":"2","author":"JR Quesada","year":"1982","unstructured":"Quesada JR, Gutteman JU, Hersh EM: Clinical and immunological study of beta interferon by intramuscular route in patients with metastatic breast cancer. Interferon Res 2:593\u2013599, 1982","journal-title":"Interferon Res"},{"key":"BF00173511_CR6","doi-asserted-by":"crossref","first-page":"598","DOI":"10.7326\/0003-4819-98-5-598","volume":"98","author":"SA Sherwin","year":"1983","unstructured":"Sherwin SA, Mayer D, Ochs JJ, Abrams PG, Knost JA, Foon KA, Fein S, Oldham RK: Recombinant leukocyte A interferon in advanced breast cancer. Ann Intern Med 98:598\u2013602, 1983","journal-title":"Ann Intern Med"},{"key":"BF00173511_CR7","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1200\/JCO.1984.2.9.1012","volume":"2","author":"HB Muss","year":"1984","unstructured":"Muss HB, Kempf RA, Martino S, Rudnick SA, Greiner J, Cooper MR, Decker D, Grunberg SM, Jackson DV, Richards F II, Samal B, Singhakowinta A, Spurr CL, Stuart JJ, White DR, Caponera M, Mitchell MS: A phase II study of recombinant \u03b1 interferon in patients with recurrent metastatic breast cancer. J Clin Oncol 2:1012\u20131016, 1984","journal-title":"J Clin Oncol"},{"key":"BF00173511_CR8","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/bjc.1984.96","volume":"49","author":"A Nethersell","year":"1984","unstructured":"Nethersell A, Smedley H, Katrak M, Wheeler T, Sikora K: Recombinant interferon in advanced breast cancer. Br J Cancer 49:615\u2013620, 1984","journal-title":"Br J Cancer"},{"key":"BF00173511_CR9","first-page":"547","volume":"69","author":"GP Sarna","year":"1985","unstructured":"Sarna GP, Figlin RA: Phase II trial of \u03b1-lymphoblastoid interferon given weekly as treatment of advanced breast cancer. Cancer Treat Rep 69:547\u2013549, 1985","journal-title":"Cancer Treat Rep"},{"key":"BF00173511_CR10","volume-title":"Preclinical studies of recombinant human interferon gamma: Effects on NK and ADCC activiities of human peripheral blood lymphocytes","author":"M Harada","year":"1983","unstructured":"Harada M, Matsumoto M: Preclinical studies of recombinant human interferon gamma: Effects on NK and ADCC activiities of human peripheral blood lymphocytes. Shionogi Res Lab, Fukashima-Ku, Osaka, Japan 1983"},{"issue":"10","key":"BF00173511_CR11","doi-asserted-by":"crossref","first-page":"5928","DOI":"10.1073\/pnas.77.10.5928","volume":"77","author":"BY Rubin","year":"1980","unstructured":"Rubin BY, Gupta SL: Differential effects of human type I and type II interferons as antiviral and antiproliferative agents. Proc Natl Acad Sci USA 77(10):5928\u20135932, 1980","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF00173511_CR12","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/0008-8749(80)90041-6","volume":"49","author":"JE Blalock","year":"1980","unstructured":"Blalock JE, Georgiades JA, Langford MP, Johnson HM: Purified human immune interferon has more potent anticellular activity than fibroblast or leukocyte interferon. Cell Immunol 49:390\u2013394, 1980","journal-title":"Cell Immunol"},{"key":"BF00173511_CR13","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1002\/1097-0142(197703)39:3<1289::AID-CNCR2820390340>3.0.CO;2-F","volume":"39","author":"JL Hayward","year":"1977","unstructured":"Hayward JL, Carbone PP, Heuson JC, Kumaokas SA, Rubens RD: Assessment of response to therapy in advanced breast cancer. Cancer 39:1289\u20131293, 1977","journal-title":"Cancer"},{"key":"BF00173511_CR14","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","volume":"47","author":"B Miller","year":"1981","unstructured":"Miller B, Hoogstraten B, Staquet M, Winker A: Reporting results of cancer treatment. Cancer 47:207\u2013214, 1981","journal-title":"Cancer"},{"key":"BF00173511_CR15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0090-1229(85)90042-X","volume":"36","author":"C-M Liang","year":"1985","unstructured":"Liang C-M, Herren S, Fountoulakis M, Otto B, Hirschi M, Gutzwiller E, Gerlis L: Analysis of antibody response in patients receiving recombinant Escherichia coli-derived human interferon-gamma. Clin Immunol Immunopath 36:95\u2013100, 1985","journal-title":"Clin Immunol Immunopath"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00173511.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/BF00173511\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00173511","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00173511.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:34:50Z","timestamp":1678559690000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/BF00173511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1986,12]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1986,12]]}},"alternative-id":["BF00173511"],"URL":"https:\/\/doi.org\/10.1007\/bf00173511","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[1986,12]]}}}